Stage one · today
Agriculture that trains
A working outdoor medical cannabis operation in the Dão. Revenue comes from flower. Every season instruments the models and field-tests the hardware on a crop we own.
Why this works
Four things that are true of Siren and of almost nobody else in European agricultural technology.
We own the field
The land in Tondela is ours, freehold and on the balance sheet, while most agricultural-AI companies are still negotiating access to somebody else's crop. We can run an experiment that costs a season without asking permission.
The data is a legal obligation
Pharmaceutical-grade cultivation requires per-plant traceability and batch records by law, not by preference. The regime that makes medical cannabis demanding to grow is the regime that compels the dataset into existence.
One genome, many climates
Cannabis is propagated clonally, so we can hold a genotype constant and let the season vary around it. Almost no field crop hands you that at scale. A clone block is a controlled experiment planted in soil.
Outdoors on purpose
Almost all medical cannabis is grown indoors, which controls away the exact variance we are trying to learn. Outdoor is lower-carbon, lower-cost, and the only place climate adaptation can be observed. An indoor grower is optimising a machine. We are learning a climate.
What we measure
Five layers, one plant, one season, recorded under a regime that requires the record to exist. Most agri-AI companies negotiate for data. We grow it.
-
DNA
Whole-genome sequencing, read against a curated cannabinoid and terpene biosynthesis panel.
-
Soil
Moisture, temperature and nutrient movement through granite-derived Dão soil, logged all season.
-
Canopy
Aerial and ground imaging of vigour, stress and phenology, plant by plant instead of block by block.
-
Climate
On-site weather against the day and night swing that made the Dão a wine region.
-
Chemistry
Cannabinoid and terpene assay at harvest, closing the loop back to genotype and season.
One company, two stages
The farm is how the technology gets built, and it pays for itself while it does.
Stage two · from 2029
Intelligence that scales
Platform revenue from the tools the farm proved: cultivar selection, irrigation intelligence and plant health, sold well beyond cannabis.
What joins them
-
Cash
Flower revenue funds the engineering years before the platform earns anything.
-
Data
Each season adds labelled genotype × environment × chemistry records that cannot be bought.
-
Model training
The farm is the ground truth the models are fitted against, and the place they are proven wrong.
-
Hardware testing
Sensors and machines are run on our own crop, at our own risk, before they reach anyone else's.
Where we are
Updated September 2026
- Licence
- Cultivation licence application filed with INFARMED. Submitted, not yet issued.
- Land
- Freehold in Tondela, owned outright. Siren has been a registered Portuguese company since 2022.
- Science
- Genomics pipeline running end to end. The selection tools built on it, including the chemotype panel and clone-fidelity screening, are in development and under pilot.
- Funding
- Bootstrapped on founder capital and friends and family. The goal has been to de-risk as much as possible before raising.
- Next
- First outdoor field season planned for 2027.
How we collaborate
Long-term relationships across the medical cannabis chain.
Pharmaceutical companies
We produce high-grade outdoor cannabis flower under EU-GACP compliance, aimed at full EU-GMP compatibility through controlled post-harvest curing. Talk to us about supply or long-term sourcing agreements.
Seed banks and breeders
We are building a genetic and chemotype library with full tracking of genotype, phenotype and environment. We welcome research collaborations, joint breeding programmes and field trials under formal agreement.
Investors and partners
We are building Siren with people who see cannabis as a stable, medical-grade crop, and Portugal as the place to prove it. If that sounds like you, we would like to talk.